PI 3-Kinase p85 alpha Antibody (572106) [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # FAB2998E

Conjugate
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
Western Blot
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Monoclonal Mouse IgG2B Clone # 572106
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant human PI 3-Kinase p85 alpha
aa Lys519-Gly644
Accession # P27986
aa Lys519-Gly644
Accession # P27986
Specificity
Detects human, mouse and rat PI 3-Kinase p85 alpha in Western blots.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for PI 3-Kinase p85 alpha Antibody (572106) [DyLight 405]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: PI 3-Kinase p85 alpha
The PI3K pathway functions in a broad range of cellular processes, so it is understandable that pathway dysfunction can lead to an array of diseases and disorders (2,5). Elevated PI3K signaling is a key feature of many cancers (5). PI3K pathway dysregulation has also been implicated in neurological, metabolic, and cardiovascular disorders (5). Furthermore, both overactivation or under-activation of the PI3K delta (p85 alpha subunit + p110 delta subunit) pathway has been shown to cause immunodeficiency and pathologies related to immune system dysfunction (2). Therapeutics to target the PI3K pathway and treat related cancers include PI3K inhibitors and, specifically, isoform-selective inhibitors which have a lot of promise when used as part of a combination therapy (5).
References
1. Okkenhaug, K., & Vanhaesebroeck, B. (2001). New responsibilities for the PI3K regulatory subunit p85 alpha. Science's STKE : signal transduction knowledge environment. https://doi.org/10.1126/stke.2001.65.pe1
2. Nunes-Santos, C. J., Uzel, G., & Rosenzweig, S. D. (2019). PI3K pathway defects leading to immunodeficiency and immune dysregulation. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2019.03.017
3. Chen, P. H., Yao, H., & Huang, L. J. (2017). Cytokine Receptor Endocytosis: New Kinase Activity-Dependent and -Independent Roles of PI3K. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2017.00078
4. Uniprot (P27986)
5. Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017). The PI3K Pathway in Human Disease. Cell. https://doi.org/10.1016/j.cell.2017.07.029
Long Name
PI 3-Kinase p85 alpha
Alternate Names
GRB1, PI 3Kinase p85 alpha, PIK3R1
Gene Symbol
PIK3R1
Additional PI 3-Kinase p85 alpha Products
Product Documents for PI 3-Kinase p85 alpha Antibody (572106) [DyLight 405]
Product Specific Notices for PI 3-Kinase p85 alpha Antibody (572106) [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...